BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pulmonary Alveolar Proteinosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Pulmonary Alveolar Pr
 oteinosis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06431776-10924@assetmemo.bio
DTSTAMP:20261121T005027Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:molgramostim: Phase 3 readout est. (NCT06431776)
DESCRIPTION:molgramostim\, phase 3\, Autoimmune Pulmonary Alveolar Proteino
 sis.\nStudy: Inhaled Molgramostim in Pediatric Participants With Autoimmun
 e Pulmonary Alveolar Proteinosis (aPAP).\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/molgramostim
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 31776
URL:https://assetmemo.bio/drug/molgramostim#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
